Somatic-cell mutations as a possible predictor of cancer risk
- Radiation Effects Research Foundation, Hiroshima (Japan); and others
The somatic-mutation theory of carcinogenesis has received strong scientific support from results of recent studies on tumor-suppressor genes. We anticipated that people among the high risk for cancer group, either through exposure to various ionizing radiations or by virtue of unique genotypes, would also manifest increased frequencies of somatic mutation. This report presents the results of two somatic-mutation assays-at the erythrocyte glycophorin A (GPA) and lymphocyte T-cell receptor (TCR) genes-in various groups at high risk for cancer development, including atomic-bomb survivors, patients with various cancers, patients administered Thorotrast, and patients with genetic disorders that make them cancer prone. Although neither the GPA-mutation nor the TCR-mutation assay detects gene mutations directly related to carcinogenesis, increased mutation frequencies were detected by both assays in many individuals among the high-risk groups and among cancer patients. We have continued to follow up those individuals who show values of about three times higher than those of the control group. Thus, these assays may prove useful for identifying high-risk cancer groups and for estimating the effects of mutagens. Such information would constitute a valuable data base for epidemiological studies.
- Sponsoring Organization:
- USDOE
- OSTI ID:
- 249950
- Journal Information:
- Health Physics, Journal Name: Health Physics Journal Issue: 5 Vol. 68; ISSN HLTPAO; ISSN 0017-9078
- Country of Publication:
- United States
- Language:
- English
Similar Records
Monitoring exposure to atomic bomb radiation by somatic mutation
Human mutation monitoring using the glycophorin A-based somatic cell assay
Related Subjects
BASIC STUDIES
56 BIOLOGY AND MEDICINE
APPLIED STUDIES
A-BOMB SURVIVORS
CARCINOGENESIS
ERYTHROCYTES
FREQUENCY ANALYSIS
GENE MUTATIONS
GENETIC RADIATION EFFECTS
IONIZING RADIATIONS
LYMPHOCYTES
MUTAGENS
NEOPLASMS
PATIENTS
RISK ASSESSMENT
SOMATIC CELLS
SOMATIC MUTATIONS
THOROTRAST